Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.21 HKD | +2.14% | +11.09% | -17.42% |
04-22 | 3Sbio Inc. Announces Management Changes | CI |
04-15 | 3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.42% | 1.85B | B | ||
-4.06% | 86.13B | A- | ||
+1.32% | 39.82B | A- | ||
-19.27% | 30.42B | B- | ||
+57.86% | 25.23B | A | ||
-16.09% | 15.36B | C | ||
-9.14% | 11.95B | D+ | ||
-17.69% | 11.6B | B- | ||
-43.00% | 11.51B | B | ||
+5.24% | 8.71B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1530 Stock
- Ratings 3SBio Inc.